In the tumor, gal-3-binding sites were detected in 40/40 (100%) of samples and sTn was expressed in 31/40 (77.5%) of gastric cancer cases, however, gal-3-binding sites and sTn were never co-localized with each other. This evidence concerns the gene LGALS3 and gastric cancer.